Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 13 Best Debt Free Dividend Stocks to Buy Now. Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) On December 12, Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $768 from $767 and kept an Equal Weight rating. The firm expects many of the policy concerns that weighed on biopharma this year to fade in 2026. As those pressures ease, attention is likely to sh ...